Restore Medical Secures $23M Series B to Revolutionize CHF Treatment with ContraBand™

Restore Medical is thrilled to announce the successful raise of $23,000,000 in its latest funding round, marking a significant milestone in our commitment to revolutionizing care for patients with congestive heart failure (CHF). As one of the foremost innovators in CHF treatment, our mission is to provide a unique solution that addresses the limitations of currently available medical treatments. CHF remains one of the leading causes of death and hospitalization worldwide, leaving millions of patients with constant, debilitating symptoms even after receiving optimized medical care. With the arrival of this new capital, we are well-positioned to further advance our groundbreaking technology—ContraBand™. This novel, catheter-delivered implant has been meticulously developed to improve the quality-of-life for CHF patients by reducing debilitating symptoms and lowering hospital readmission rates, which are crucial steps toward alleviating the physical and emotional burdens faced by patients and their families. The new funding will be dedicated to scaling production capabilities, enhancing clinical trials, and expanding our research efforts to continually refine the ContraBand™ device. Additionally, we plan to broaden our market reach and invest in strategic partnerships that accelerate its adoption within the healthcare community. We believe that this proactive investment in innovative technology, driven by our passionate team of experts, will not only transform patient care but also set a new standard for how chronic cardiac conditions are managed. As we enter this exciting phase of growth, we remain dedicated to our core vision of delivering life-changing solutions to those battling CHF, paving the way for a future where heart failure is met with hope, innovation, and improved outcomes for patients around the globe.